Granted Patent
B2
US 12,246,029 · App. 17/523,034 · Granted Mar 11, 2025
High purity RNA compositions and methods for preparation thereof
Inventors:
Stephen Hoge (Brookline, MA); William Issa (Dedham, MA); Edward J. Miracco (Arlington, MA); Jennifer Nelson (Brookline, MA); Amy E. Rabideau (Waltham, MA); Gabor Butora (Martinsville, NJ)
Assignee:
ModernaTX, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention relates to improved RNA compositions for use in therapeutic applications. The RNA compositions are particularly suited for use in human therapeutic application (e.g., in RNA therapeutics). The RNA compositions are made by improved processes, in particular, improved in vitro-transcription (IVT) processes. The invention also relates to methods for producing and purifying RNA (e.g, therapeutic RNAs), as well as methods for using the RNA compositions and therapeutic applications thereof.
Claims (34)
1. A method of producing a messenger ribonucleic acid (mRNA) that comprises an open reading frame encoding a vaccine antigen, the method comprising incubating a reaction mixture comprising a deoxyribonucleic acid (DNA), an RNA polymerase, buffer, adenosine triphosphate (ATP), cytidine triphosphate (CTP), uridine triphosphate (UTP), and guanosine triphosphate (GTP), wherein the reaction mixture comprises the GTP in an amount greater than an amount of one or more of the ATP, CTP, and UTP, wherein the reaction mixture comprises two or more of the ATP, CTP, and UTP in equimolar amounts, thereby producing the mRNA.
2. The method of claim 1 , wherein the amount of the GTP is greater than the amount of the UTP.
3. The method of claim 1 , wherein the amount of the ATP is greater than the amount of the UTP.
4. The method of claim 1 , wherein the amount of the CTP is greater than the amount of the UTP.
5. The method of claim 1 , wherein the reaction mixture comprises an at least 2:1 ratio of the GTP to the ATP, an at least 2:1 ratio of the GTP to the CTP, and an at least 4:1 ratio of the GTP to the UTP.
6. The method of claim 1 , wherein the reaction mixture comprises a 2:1 ratio of the GTP to the ATP, a 2:1 ratio of the GTP to the CTP, and a 4:1 ratio of the GTP to the UTP.
7. The method of claim 1 , wherein the RNA polymerase is selected from T7 polymerase, T3 polymerase, and SP6 polymerase.
8. The method of claim 7 , wherein the RNA polymerase is T7 polymerase.
9. The method of claim 1 , wherein the DNA is cDNA.
10. The method of claim 1 , wherein the buffer comprises magnesium.
11. The method of claim 1 , wherein the reaction mixture further comprises dithiothreitol (DTT), spermidine, an RNase inhibitor, pyrophosphatase, or a combination thereof.
12. The method of claim 1 , wherein the reaction mixture is incubated at 25 degrees Celsius or at 37 degrees Celsius.
13. The method of claim 1 , wherein the produced mRNA is less immunogenic than an mRNA made by a comparable method but with equimolar amounts of the GTP, ATP, CTP and UTP in the reaction mixture.
14. The method of claim 1 , wherein the produced mRNA has less double stranded impurities than an mRNA made by a comparable method but with equimolar amounts of the GTP, ATP, CTP and UTP in the reaction mixture.
15. The method of claim 1 , wherein the reaction mixture does not contain an RNase inhibitor.
16. The method of claim 1 , wherein less than 1% of the total mass of RNA in the reaction mixture is a reverse complement transcription product.
17. The method of claim 16 , wherein less than 0.1% of the total mass of RNA in the reaction mixture is a reverse complement transcription product.
18. A method of producing a messenger ribonucleic acid (mRNA) that comprises an open reading frame encoding a therapeutic protein or peptide, the method comprising incubating a reaction mixture comprising a deoxyribonucleic acid (DNA), an RNA polymerase, buffer, adenosine triphosphate (ATP), cytidine triphosphate (CTP), uridine triphosphate (UTP), and guanosine triphosphate (GTP), wherein the reaction mixture comprises the GTP in an amount greater than an amount of one or more of the ATP, CTP, and UTP, wherein the reaction mixture comprises two or more of the ATP, CTP, and UTP in equimolar amounts, thereby producing the mRNA.
19. The method of claim 18 , wherein the amount of the GTP is greater than the amount of the UTP.
20. The method of claim 18 , wherein the amount of the ATP is greater than the amount of the UTP.
21. The method of claim 18 , wherein the amount of the CTP is greater than the amount of the UTP.
22. The method of claim 18 , wherein the reaction mixture comprises an at least 2:1 ratio of the GTP to the ATP, an at least 2:1 ratio of the GTP to the CTP, and an at least 4:1 ratio of the GTP to the UTP.
23. The method of claim 18 , wherein the reaction mixture comprises a 2:1 ratio of the GTP to the ATP, a 2:1 ratio of the GTP to the CTP, and a 4:1 ratio of the GTP to the UTP.
24. The method of claim 18 , wherein the RNA polymerase is selected from T7 polymerase, T3 polymerase, and SP6 polymerase.
25. The method of claim 24 , wherein the RNA polymerase is T7 polymerase.
26. The method of claim 18 , wherein the DNA is cDNA.
27. The method of claim 18 , wherein the buffer comprises magnesium.
28. The method of claim 18 , wherein the reaction mixture further comprises dithiothreitol (DTT), spermidine, an RNase inhibitor, pyrophosphatase, or a combination thereof.
29. The method of claim 18 , wherein the reaction mixture is incubated at 25 degrees Celsius or at 37 degrees Celsius.
30. The method of claim 18 , wherein the produced mRNA is less immunogenic than an mRNA made by a comparable method but with equimolar amounts of the GTP, ATP, CTP and UTP in the reaction mixture.
31. The method of claim 18 , wherein the produced mRNA has less double stranded impurities than an mRNA made by a comparable method but with equimolar amounts of the GTP, ATP, CTP and UTP in the reaction mixture.
32. The method of claim 18 , wherein the reaction mixture does not contain an RNase.
33. The method of claim 18 , wherein less than 1% of the total mass of RNA in the reaction mixture is a reverse complement transcription product.
34. The method of claim 33 , wherein less than 0.1% of the total mass of RNA in the reaction mixture is a reverse complement transcription product.
Assignments (2)
SECURITY INTEREST
Recorded Nov 19, 2025
From: MODERNATX, INC.
To: ARES CAPITAL CORPORATION, AS AGENT
Reel/Frame 073634/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 5, 2022
From: HOGE, STEPHEN; ISSA, WILLIAM; MIRACCO, EDWARD J.; NELSON, JENNIFER; RABIDEAU, AMY E.; BUTORA, GABOR
To: MODERNATX, INC.
Reel/Frame 059505/0480 →
Continuity (3)
Continuation
16333330
Provisional Application
62394711
· Sep 14, 2016
References Cited (400)
US 5256555A
· Milburn et al.
· 1993
[cited by applicant]
US 5756264A
· Schwartz et al.
· 1998
[cited by applicant]
US 6022715A
· Merenkova et al.
· 2000
[cited by applicant]
US 6096503A
· Sutcliffe et al.
· 2000
[cited by applicant]
US 6100024A
· Hudson et al.
· 2000
[cited by applicant]
US 6528262B1
· Gilad et al.
· 2003
[cited by applicant]
US 8383340B2
· Ketterer et al.
· 2013
[cited by applicant]
US 8710200B2
· Schrum et al.
· 2014
[cited by applicant]
US 8754062B2
· De Fougerolles et al.
· 2014
[cited by applicant]
US 8822663B2
· Schrum et al.
· 2014
[cited by applicant]
US 8980864B2
· Hoge et al.
· 2015
[cited by applicant]
US 8999380B2
· Bancel et al.
· 2015
[cited by applicant]
US 9221891B2
· Bancel et al.
· 2015
[cited by applicant]
US 9283287B2
· Bancel et al.
· 2016
[cited by applicant]
US 9303079B2
· Bancel et al.
· 2016
[cited by applicant]
US 9464124B2
· Bancel et al.
· 2016
[cited by applicant]
US 9512456B2
· Wang et al.
· 2016
[cited by applicant]
US 9533047B2
· de Fougerolles et al.
· 2017
[cited by applicant]
US 9572896B2
· Bancel et al.
· 2017
[cited by applicant]
US 9597380B2
· Chakraborty et al.
· 2017
[cited by applicant]
US 9675668B2
· Bancel et al.
· 2017
[cited by applicant]
US 9868691B2
· Benenato et al.
· 2018
[cited by applicant]
US 9872900B2
· Ciaramella et al.
· 2018
[cited by applicant]
US 20010001066A1
· Cezayirli et al.
· 2001
[cited by applicant]
US 20010005506A1
· Cezayirli et al.
· 2001
[cited by applicant]
US 20030165849A1
· Zhang et al.
· 2003
[cited by applicant]
US 20050287539A1
· Labourier et al.
· 2005
[cited by applicant]
US 20060247195A1
· Ray
· 2006
[cited by applicant]
US 20070281336A1
· Jendrisak et al.
· 2007
[cited by applicant]
US 20080220471A1
· Davis et al.
· 2008
[cited by applicant]
US 20100028943A1
· Thomas et al.
· 2010
[cited by applicant]
US 20100048883A1
· Ketterer et al.
· 2010
[cited by applicant]
US 20100291156A1
· Barner et al.
· 2010
[cited by applicant]
US 20110143397A1
· Karikóet al.
· 2011
[cited by applicant]
US 20120301955A1
· Thomas et al.
· 2012
[cited by applicant]
US 20130102034A1
· Schrum et al.
· 2013
[cited by applicant]
US 20130236974A1
· De Fougerolles
· 2013
[cited by applicant]
US 20130245103A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20130259923A1
· Bancel et al.
· 2013
[cited by applicant]
US 20130266640A1
· De Fougerolles et al.
· 2013
[cited by applicant]
US 20140142290A1
· Madden et al.
· 2014
[cited by applicant]
US 20140147432A1
· Bancel et al.
· 2014
[cited by applicant]
US 20140148502A1
· Bancel et al.
· 2014
[cited by applicant]
US 20140193482A1
· Bancel et al.
· 2014
[cited by applicant]
US 20140206752A1
· Afeyan et al.
· 2014
[cited by applicant]
US 20140328825A1
· Meis et al.
· 2014
[cited by applicant]
US 20140378538A1
· Bancel
· 2014
[cited by applicant]
US 20150051268A1
· Bancel et al.
· 2015
[cited by applicant]
US 20150056253A1
· Bancel et al.
· 2015
[cited by applicant]
US 20150141499A1
· Bancel et al.
· 2015
[cited by applicant]
US 20150307542A1
· Roy et al.
· 2015
[cited by applicant]
US 20150315541A1
· Bancel et al.
· 2015
[cited by applicant]
US 20160024140A1
· Issa et al.
· 2016
[cited by applicant]
US 20160024141A1
· Issa et al.
· 2016
[cited by applicant]
US 20160032273A1
· Shahrokh et al.
· 2016
[cited by applicant]
US 20160032316A1
· Weissman et al.
· 2016
[cited by applicant]
US 20160038612A1
· Hoge et al.
· 2016
[cited by applicant]
US 20160194368A1
· Hoge et al.
· 2016
[cited by applicant]
US 20160194625A1
· Hoge et al.
· 2016
[cited by applicant]
US 20160243221A1
· Hoge et al.
· 2016
[cited by applicant]
US 20160251729A1
· Chinnaiyan et al.
· 2016
[cited by applicant]
US 20160317647A1
· Ciaramella et al.
· 2016
[cited by applicant]
US 20170043037A1
· Kariko et al.
· 2017
[cited by applicant]
US 20170202979A1
· Chakraborty et al.
· 2017
[cited by applicant]
US 20170204152A1
· Nelson et al.
· 2017
[cited by applicant]
US 20170247670A1
· Ong et al.
· 2017
[cited by applicant]
US 20170130255A1
· Wang et al.
· 2017
[cited by applicant]
US 20170340724A1
· Ciaramella et al.
· 2017
[cited by applicant]
US 20170340725A1
· Ciaramella et al.
· 2017
[cited by applicant]
US 20180000953A1
· Almarsson et al.
· 2018
[cited by applicant]
US 20180002393A1
· Bancel et al.
· 2018
[cited by applicant]
US 20180028645A1
· Ciaramella et al.
· 2018
[cited by applicant]
US 20180028664A1
· Besin et al.
· 2018
[cited by applicant]
US 20180237849A1
· Thompson
· 2018
[cited by applicant]
US 20180243225A1
· Ciaramella
· 2018
[cited by applicant]
US 20180243230A1
· Smith
· 2018
[cited by applicant]
US 20180256628A1
· Hoge et al.
· 2018
[cited by applicant]
US 20180271795A1
· Martini et al.
· 2018
[cited by applicant]
US 20180271970A1
· Ciaramella et al.
· 2018
[cited by applicant]
US 20180273977A1
· Mousavi et al.
· 2018
[cited by applicant]
US 20180274009A1
· Marquardt et al.
· 2018
[cited by applicant]
US 20180280496A1
· Ciaramella et al.
· 2018
[cited by applicant]
US 20180289792A1
· Ciaramella et al.
· 2018
[cited by applicant]
US 20180303929A1
· Ciaramella et al.
· 2018
[cited by applicant]
US 20180311336A1
· Ciaramella et al.
· 2018
[cited by applicant]
US 20180311343A1
· Huang et al.
· 2018
[cited by applicant]
US 20180312549A1
· Ciaramella
· 2018
[cited by applicant]
US 20180363019A1
· Hoge
· 2018
[cited by applicant]
US 20180369374A1
· Frederick et al.
· 2018
[cited by applicant]
US 20180371047A1
· Ticho et al.
· 2018
[cited by applicant]
US 20190002851A1
· Miller et al.
· 2019
[cited by applicant]
US 20190002890A1
· Martini et al.
· 2019
[cited by applicant]
US 20190008938A1
· Ciaramella et al.
· 2019
[cited by applicant]
US 20190085368A1
· Bancel et al.
· 2019
[cited by applicant]
US 20190099481A1
· Ciaramella et al.
· 2019
[cited by applicant]
US 20190125839A1
· Frederick et al.
· 2019
[cited by applicant]
US 20190175517A1
· Martini et al.
· 2019
[cited by applicant]
US 20190175727A1
· Huang et al.
· 2019
[cited by applicant]
US 20190192646A1
· Cohen et al.
· 2019
[cited by applicant]
US 20190192653A1
· Hoge et al.
· 2019
[cited by applicant]
US 20190275170A1
· Benenato et al.
· 2019
[cited by applicant]
US 20190298657A1
· Martini et al.
· 2019
[cited by applicant]
US 20190298658A1
· Benenato
· 2019
[cited by applicant]
US 20190300906A1
· Martini et al.
· 2019
[cited by applicant]
US 20190314292A1
· Benenato et al.
· 2019
[cited by applicant]
US 20190336452A1
· Brader
· 2019
[cited by applicant]
US 20190351040A1
· Valiante et al.
· 2019
[cited by applicant]
US 20190382774A1
· Hoge et al.
· 2019
[cited by applicant]
US 20190390181A1
· Benenato et al.
· 2019
[cited by applicant]
US 20200030432A1
· Ciaramella et al.
· 2020
[cited by applicant]
US 20200032274A1
· Mauger et al.
· 2020
[cited by applicant]
US 20200038499A1
· Narayanan et al.
· 2020
[cited by applicant]
US 20200054737A1
· Ciaramella et al.
· 2020
[cited by applicant]
US 20200069599A1
· Smith et al.
· 2020
[cited by applicant]
US 20200071689A1
· Miracco
· 2020
[cited by applicant]
US 20200085916A1
· Martini et al.
· 2020
[cited by applicant]
US 20200109420A1
· Brito et al.
· 2020
[cited by applicant]
US 20200129445A1
· Patel et al.
· 2020
[cited by applicant]
US 20200129608A1
· Ciaramella et al.
· 2020
[cited by applicant]
US 20200129615A1
· Ciaramella et al.
· 2020
[cited by applicant]
US 20200239869A1
· Issa et al.
· 2020
[cited by applicant]
US 20200254086A1
· Hoge et al.
· 2020
[cited by applicant]
US 20200282047A1
· Ciaramella et al.
· 2020
[cited by applicant]
US 20200306191A1
· Schariter et al.
· 2020
[cited by applicant]
US 20200338004A1
· Hansson et al.
· 2020
[cited by applicant]
US 20200368162A1
· Martini
· 2020
[cited by applicant]
US 20210046173A1
· Ciaramella et al.
· 2021
[cited by applicant]
US 20210087135A1
· Benenato et al.
· 2021
[cited by applicant]
US 20210163919A1
· Issa et al.
· 2021
[cited by applicant]
US 20210187097A1
· Ciaramella et al.
· 2021
[cited by applicant]
US 20210206818A1
· Huang et al.
· 2021
[cited by applicant]
US 20210217484A1
· Giessel et al.
· 2021
[cited by applicant]
US 20210228707A1
· Mektar et al.
· 2021
[cited by applicant]
US 20210268086A1
· Zhong et al.
· 2021
[cited by applicant]
US 20210309976A1
· Dousis et al.
· 2021
[cited by applicant]
US 20210378980A1
· Horhota et al.
· 2021
[cited by applicant]
US 20220047518A1
· Hennessy et al.
· 2022
[cited by applicant]
US 20220054653A1
· Martini et al.
· 2022
[cited by applicant]
US 20220062408A1
· Kramarczyk et al.
· 2022
[cited by applicant]
US 20220125899A1
· Ashburn et al.
· 2022
[cited by applicant]
US 20220236253A1
· Hopson
· 2022
[cited by applicant]
US 20220347292A1
· Panther et al.
· 2022
[cited by applicant]
US 20220348900A1
· Shamashkin et al.
· 2022
[cited by applicant]
US 20220349006A1
· Amato et al.
· 2022
[cited by applicant]
US 20230142529A1
· White et al.
· 2023
[cited by applicant]
US 20230181481A1
· White et al.
· 2023
[cited by applicant]
US 20230190761A1
· Brader et al.
· 2023
[cited by applicant]
US 20230212645A1
· Marquardt et al.
· 2023
[cited by applicant]
US 20230287437A1
· Smith et al.
· 2023
[cited by applicant]
US 20230338506A1
· Shaw et al.
· 2023
[cited by applicant]
US 20230346914A1
· Stewart-Jones et al.
· 2023
[cited by applicant]
US 20230355743A1
· Stewart-Jones et al.
· 2023
[cited by applicant]
US 20240100145A1
· Bollman et al.
· 2024
[cited by applicant]
US 20240100151A1
· Carfi et al.
· 2024
[cited by applicant]
US 20240139309A1
· Carfi et al.
· 2024
[cited by applicant]
US 20240173400A1
· Ciaramella et al.
· 2024
[cited by applicant]
US 20240181030A1
· Himansu et al.
· 2024
[cited by applicant]
US 20240207392A1
· Chandramouli et al.
· 2024
[cited by applicant]
US 20240209068A1
· Deal et al.
· 2024
[cited by applicant]
US 20240226028A1
· Goldman et al.
· 2024
[cited by applicant]
US 20240226277A1
· Nachbagauer et al.
· 2024
[cited by applicant]
US 20240229109A1
· Rabideau et al.
· 2024
[cited by applicant]
US 20240238211A1
· Brader et al.
· 2024
[cited by applicant]
US 20240285754A1
· Stewart-Jones
· 2024
[cited by applicant]
US 20240293534A1
· Stewart-Jones
· 2024
[cited by applicant]
US 20240299531A1
· Stewart-Jones
· 2024
[cited by applicant]
CN 102947450A
· 2013
[cited by applicant]
CN 105051213A
· 2015
[cited by applicant]
CN 106244608A
· 2016
[cited by applicant]
CN 106661621A
· 2017
[cited by applicant]
CN 111032863A
· 2020
[cited by applicant]
EP 2092064B1
· 2010
[cited by applicant]
EP 3119873A1
· 2017
[cited by applicant]
WO WO1995008626A1
· 1995
[cited by applicant]
WO WO200248310A2
· 2002
[cited by applicant]
WO WO2002048310A2
· 2002
[cited by applicant]
WO WO2005118857A2
· 2005
[cited by applicant]
WO WO2008077592A1
· 2008
[cited by applicant]
WO WO2011005799A2
· 2011
[cited by applicant]
WO WO2011071931A2
· 2011
[cited by applicant]
WO WO2012038450A1
· 2012
[cited by applicant]
WO WO2013090648A1
· 2013
[cited by applicant]
WO WO2013102203A1
· 2013
[cited by applicant]
WO WO2014140211A1
· 2014
[cited by applicant]
WO WO2014144711A1
· 2014
[cited by applicant]
WO WO2014152030A1
· 2014
[cited by applicant]
WO WO2014152966A1
· 2014
[cited by applicant]
WO WO2014159813A1
· 2014
[cited by applicant]
WO WO2014160243A1
· 2014
[cited by applicant]
WO WO2015085318A2
· 2015
[cited by applicant]
WO WO2015188933A1
· 2015
[cited by applicant]
WO WO2016164762A1
· 2016
[cited by applicant]
WO WO2016174227A1
· 2016
[cited by applicant]
WO WO2016201377A1
· 2016
[cited by applicant]
WO WO2017011773A2
· 2017
[cited by applicant]
WO WO2017015457A1
· 2017
[cited by applicant]
WO WO2017015463A1
· 2017
[cited by applicant]
WO WO2017019935A1
· 2017
[cited by applicant]
WO WO2017020026A1
· 2017
[cited by applicant]
WO Wo2017031232A1
· 2017
[cited by applicant]
WO WO2017031241A1
· 2017
[cited by applicant]
WO WO2017062513A1
· 2017
[cited by applicant]
WO WO2017066789A1
· 2017
[cited by applicant]
WO WO2017070601A1
· 2017
[cited by applicant]
WO WO2017070616A1
· 2017
[cited by applicant]
WO WO2017070618A1
· 2017
[cited by applicant]
WO WO2017070620A1
· 2017
[cited by applicant]
WO WO2017070622A1
· 2017
[cited by applicant]
WO WO2017070623A1
· 2017
[cited by applicant]
WO WO2017112865A1
· 2017
[cited by applicant]
WO WO2017127750A1
· 2017
[cited by applicant]
WO WO2017201333A1
· 2017
[cited by applicant]
WO WO2017201340A1
· 2017
[cited by applicant]
WO WO2017201342A1
· 2017
[cited by applicant]
WO WO2017201347A1
· 2017
[cited by applicant]
WO WO2018053209A1
· 2018
[cited by applicant]
WO WO2018075980A1
· 2018
[cited by applicant]
WO WO2018081459A1
· 2018
[cited by applicant]
WO WO2018081462A1
· 2018
[cited by applicant]
WO WO2018089851A1
· 2018
[cited by applicant]
WO WO2018107088A1
· 2018
[cited by applicant]
WO WO2018111967A1
· 2018
[cited by applicant]
WO WO2018144082A1
· 2018
[cited by applicant]
WO WO2018144778A1
· 2018
[cited by applicant]
WO WO2018157009A1
· 2018
[cited by applicant]
WO WO2018170245A1
· 2018
[cited by applicant]
WO WO2018170256A1
· 2018
[cited by applicant]
WO WO2018170260A1
· 2018
[cited by applicant]
WO WO2018170270A1
· 2018
[cited by applicant]
WO WO2018170347A1
· 2018
[cited by applicant]
WO WO2018175783A1
· 2018
[cited by applicant]
WO WO2018187590A2
· 2018
[cited by applicant]
WO WO2018200737A1
· 2018
[cited by applicant]
WO WO2018232355A1
· 2018
[cited by applicant]
WO WO2018232357A1
· 2018
[cited by applicant]
WO WO2019018765A1
· 2019
[cited by applicant]
WO WO2019036670A1
· 2019
[cited by applicant]
WO WO2019036682A1
· 2019
[cited by applicant]
WO WO2019036683A1
· 2019
[cited by applicant]
WO WO2019036685A1
· 2019
[cited by applicant]
WO WO2019103993A1
· 2019
[cited by applicant]
WO WO2020056370A1
· 2020
[cited by applicant]
WO WO2020061284A1
· 2020
[cited by applicant]
WO WO2020061295A1
· 2020
[cited by applicant]
WO WO2020061367A1
· 2020
[cited by applicant]
WO WO2020097291A1
· 2020
[cited by applicant]
WO WO2020172239A1
· 2020
[cited by applicant]
WO Wo2020185811A1
· 2020
[cited by applicant]
WO WO2020190750A1
· 2020
[cited by applicant]
WO WO2020243561A1
· 2020
[cited by applicant]
WO WO2021030533A1
· 2021
[cited by applicant]
WO WO2021050864A1
· 2021
[cited by applicant]
WO WO2021055811A1
· 2021
[cited by applicant]
WO WO2021155243A1
· 2021
[cited by applicant]
WO WO2021155274A1
· 2021
[cited by applicant]
WO WO2021159040A2
· 2021
[cited by applicant]
WO WO2021159130A2
· 2021
[cited by applicant]
WO WO2021211343A1
· 2021
[cited by applicant]
WO WO2021222304A1
· 2021
[cited by applicant]
WO WO2021231929A1
· 2021
[cited by applicant]
WO WO2021231963A1
· 2021
[cited by applicant]
WO WO2021237084A1
· 2021
[cited by applicant]
WO WO2021247817A1
· 2021
[cited by applicant]
WO WO2022032154A2
· 2022
[cited by applicant]
WO WO2022067010A1
· 2022
[cited by applicant]
WO WO2022212442A1
· 2022
[cited by applicant]
WO WO2022221335A1
· 2022
[cited by applicant]
WO WO2022221336A1
· 2022
[cited by applicant]
WO WO2022226277A1
· 2022
[cited by applicant]
WO WO2022241103A1
· 2022
[cited by applicant]
WO WO2022245888A1
· 2022
[cited by applicant]
WO WO2022266389A1
· 2022
[cited by applicant]
WO WO2023283642A2
· 2023
[cited by applicant]
WO WO2023283645A1
· 2023
[cited by applicant]
WO WO2023283651A1
· 2023
[cited by applicant]
WO WO2023014649A1
· 2023
[cited by applicant]
WO WO2023018773A1
· 2023
[cited by applicant]
WO WO2023018923A1
· 2023
[cited by applicant]
WO WO2023019181A1
· 2023
[cited by applicant]
WO WO2023056401A1
· 2023
[cited by applicant]
WO WO2023069625A1
· 2023
[cited by applicant]
WO WO2023069895A1
· 2023
[cited by applicant]
WO WO2023069900A1
· 2023
[cited by applicant]
WO WO2023076658A1
· 2023
[cited by applicant]
WO WO2023081311A1
· 2023
[cited by applicant]
WO WO2023092069A1
· 2023
[cited by applicant]
WO WO2023107999A2
· 2023
[cited by applicant]
WO WO2023114307A1
· 2023
[cited by applicant]
WO WO2023132885A1
· 2023
[cited by applicant]
WO WO2023137149A1
· 2023
[cited by applicant]
WO WO2023150256A1
· 2023
[cited by applicant]
WO WO2023154818A1
· 2023
[cited by applicant]
WO Wo2023196914A1
· 2023
[cited by applicant]
WO WO2023201204A1
· 2023
[cited by applicant]
WO WO2023201294A1
· 2023
[cited by applicant]
WO WO2023201296A1
· 2023
[cited by applicant]
WO WO2023212696A1
· 2023
[cited by applicant]
WO WO2023225524A1
· 2023
[cited by applicant]
WO WO2023250119A1
· 2023
[cited by applicant]
WO WO2024010993A1
· 2024
[cited by applicant]
WO WO2024015890A1
· 2024
[cited by applicant]
WO WO2024026005A1
· 2024
[cited by applicant]
WO WO2024030369A1
· 2024
[cited by applicant]
WO Wo2024050483A1
· 2024
[cited by applicant]
WO WO2024097874A1
· 2024
[cited by applicant]
WO WO2024123978A1
· 2024
[cited by applicant]
WO WO2024151811A1
· 2024
[cited by applicant]
WO WO2024163465A1
· 2024
[cited by applicant]
By Blumenthal, T. (Proc. Natl. Acad. Sci. USA, vol. 77, No. 5, pp. 2601-2605 (1980)). (Year: 1980).
[cited by examiner]
Schneider et al (Methods in Enzymology, vol. 370, pp. 606-617 (2003)). (Year: 2003).
[cited by examiner]
U.S. Appl. No. 17/523,060 ( (Year: 2021).
[cited by examiner]
International Search Report and Written Opinion for Application No. PCT/US2017/051674, mailed Dec. 14, 2017.
[cited by applicant]
[No Author Listed], MEGAscript Kit Product Manual, Oct. 27, 2009. Ambion/Invitrogen website: http://tools.invitrogen.com/contenl/sfs/manuals/ cms_072987.pdf, (last accessed Mar. 17, 2013). 29 pages.
[cited by applicant]
Andrews-Pfannkoch, C. et al., Hydroxyapatite-mediated separation of double-stranded DNA, single-stranded DNA, and RNA genomes from natural viral assemblages. Appl Environ Microbiol. Aug. 2010;76(15):5039-45. Epub Jun. 1…
[cited by applicant]
Brennan, Ribonucleoside triphosphate concentration-dependent termination of bacteriophage SP01 transcription in vitro by Bacillus subtilis RNA polymerase. Virology. Jun. 1984;135(2):555-60. doi: 10.1016/0042-6822(84)902…
[cited by applicant]
Devoldere et al., Evading innate immunity in nonviral mRNA delivery: don't shoot the messenger. Drug Discov Today. Jan. 2016;21(1):11-25. doi: 10.1016/j.drudis.2015.07.009. Epub Jul. 23, 2015.
[cited by applicant]
Easton et al., Rapid, nondenaturing RNA purification using weak anion-exchange fast performance liquid chromatography. RNA. Mar. 2010;16(3):647-53. Epub Jan. 25, 2010.
[cited by applicant]
Furuichi, Caps on Eukaryotic mRNAs. eLS. John Wiley & Sons. Jul. 1-12, 2014.
[cited by applicant]
Georgopoulos et al., Use of high-performance liquid chromatographic fractionation of large RNA molecules in the assay of group I intron ribozyme activity. J Chromatogr A. Jan. 28, 2000;868(1):109-14.
[cited by applicant]
Gruegelsiepe et al., Handbook of RNA Biochemistry, ed. R.K. Hartmann, Part L1, pp. 3-21, 2005.
[cited by applicant]
Hartmann et al., Handbook of RNA Biochemistry, Second Edition, “Part I RNA Synthesis and Detection.” 2014. p. 1-27.
[cited by applicant]
Jia et al., Kinetic mechanism of GTP binding and RNA synthesis during transcription initiation by bacteriophage T7 RNA polymerase. J Biol Chem. Nov. 28, 1997;272(48):30147-53. doi: 10.1074/jbc.272.48.30147.
[cited by applicant]
Kariko et al., Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. Nov. 2011;39(21):e142.
[cited by applicant]
Kauffman et al., Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs. Nano Lett. Nov. 11, 2015;15(11):7300-6. doi: 10.1021/acs.nanolett.5b…
[cited by applicant]
Kern et al., Application of a Fed-Batch System to Produce RNA by in Vitro Transcription. Biotechnol Prog. Mar.-Apr. 1999;15(2):174-84. doi: 10.1021/bp990008g.
[cited by applicant]
Koch, G., et al., Quantitative Studies on the Infectivity of ribonucleic acid from partially purified and highly purified poliovirus preparations. Virology. Mar. 1960; 10(3): 329-343.
[cited by applicant]
Lewandowski, L.J. et al., Separation of the infectious ribonucleic acid of potato spindle tuber virus from double-stranded ribonucleic acid of plant tissue extracts. J Virol. Nov. 1971;8(5):809-12.
[cited by applicant]
Mellits, K.H. et al., Removal of double-stranded contaminants from RNA transcripts: synthesis of adenovirus VA RNAI from a T7 vector. Nucleic Acids Res. Sep. 25, 1990;18(18):5401-6.
[cited by applicant]
Nedialkov et al., NTP-driven translocation by human RNA polymerase II. J Biol Chem. May 16, 2003;278(20):18303-12. doi: 10.1074/jbc.M301103200. Epub Mar. 13, 2003.
[cited by applicant]
Ouranidis et al., Pharma 4.0 Continuous mRNA Drug Products Manufacturing. Pharmaceutics. Aug. 31, 2021;13(9):1371. doi: 10.3390/pharmaceutics13091371.
[cited by applicant]
Sahin et al., mRNA-based therapeutics—developing a new class of drugs. Nat Rev Drug Discov. Oct. 2014;13(10):759-80. doi: 10.1038/nrd4278. Epub Sep. 19, 2014.
[cited by applicant]
Schmidt et al., Fast and Flexible mRNA Vaccine Manufacturing as a Solution to Pandemic Situations by Adopting Chemical Engineering Good Practice—Continuous Autonomous Operation in Stainless Steel Equipment Concepts. Pro…
[cited by applicant]
Steinle et al., Concise Review: Application of In Vitro Transcribed Messenger RNA for Cellular Engineering and Reprogramming: Progress and Challenges. Stem Cells. Jan. 2017;35(1):68-79. doi: 10.1002/stem.2402. Epub Jun.…
[cited by applicant]
Thess et al., Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals. Mol Ther. Sep. 2015;23(9):1456-64. doi: 10.1038/mt.2015.103. Epub Jun. 8, 2015.
[cited by applicant]
Wang et al., Purification of the messenger ribonucleic acid for the lipoprotein of the
[cited by applicant]
Weissman et al., HPLC purification of in vitro transcribed long RNA. Methods Mol Biol. 2013;969:43-54. doi: 10.1007/978-1-62703-260-5_3.
[cited by applicant]
[No Author Listed], DNA-directed RNA polymerase; EC=2.7.7.6. Uniprot Accession No. A0A316S4Q1. Uniprot. Oct. 10, 2018. 1 Page.
[cited by applicant]
[No Author Listed], DNA-directed RNA polymerase; EC=2.7.7.6. Uniprot Accession No. E4LAB3. Uniprot. Feb. 8, 2011. 2 Pages.
[cited by applicant]
[No Author Listed], Guidelines on the quality, safety and efficacy of biotherapeutic protein products prepared by recombinant DNA technology. WHO Expert Committee on Biological Standardization. Sixty-fourth report. Jun.…
[cited by applicant]
[No Author Listed], T7RNAP [Cloning vector pTara:500*]. GenBank Accession No. ATP60600. Nov. 4, 2017. Retrieved on Jan. 19, 2024 from <https://www.ncbi.nlm.nih.gov/protein/ATP60600.1?report=genbank&log$=protalign&blast_…
[cited by applicant]
Ballal et al., Fluorescent oligonucleotides can serve as suitable alternatives to radiolabeled oligonucleotides. J Biomol Tech. Sep. 2009;20(4):190-4.
[cited by applicant]
Chamberlin et al., Characterization of T7-specific ribonucleic acid polymerase. II. Inhibitors of the enzyme and their application to the study of the enzymatic reaction. J Biol Chem. Mar. 25, 1973;248(6):2245-50.
[cited by applicant]
Govind et al., Primer-independent initiation of RNA synthesis by SeMV recombinant RNA-dependent RNA polymerase. Virology. Jun. 5, 2010;401(2):280-92. doi: 10.1016/j.virol.2010.02.025. Epub Mar. 23, 2010.
[cited by applicant]
Karikó et al., Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. Nov. 2008; 16(11):1833-40. Epub Sep. 16, 2008.
[cited by applicant]
Karikó et al., Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. Aug. 2005;23(2):165-75.
[cited by applicant]
Kern et al., Application of solution equilibrium analysis to in vitro RNA transcription. Biotechnol Prog. Nov.-Dec. 1997;13(6):747-56. doi: 10.1021/bp970094p.
[cited by applicant]
Koubek et al., Strong anion-exchange fast performance liquid chromatography as a versatile tool for preparation and purification of RNA produced by in vitro transcription. RNA. Oct. 2013;19(10):1449-59. doi: 10.1261/rna…
[cited by applicant]
Liu et al., Real-time monitoring in vitro transcription using molecular beacons. Anal Biochem. Jan. 1, 2002;300(1):40-5. doi: 10.1006/abio.2001.5446.
[cited by applicant]
Nilsen et al., High-yield synthesis of RNA using T7 RNA polymerase and plasmid DNA or oligonucleotide templates. Cold Spring Harb Protoc. Nov. 1, 2013;2013(11):pdb.prot078535. doi: 10.1101/pdb.prot078535.
[cited by applicant]
Nomura et al., Real-Time Monitoring of in vitro Transcriptional RNA by Using Fluorescence Correlation Spectroscopy. ChemBioChem. Dec. 3, 2004;5(12):1701-1703.
[cited by applicant]
Schlake et al., Developing mRNA-vaccine technologies. RNA Biol. Nov. 2012;9(11):1319-30. doi: 10.4161/rna.22269. Epub Oct. 12, 2012.
[cited by applicant]
Sei-Lida et al., Real-time monitoring of in vitro transcriptional RNA synthesis using fluorescence resonance energy transfer. Nucleic Acids Res. Jun. 15, 2000;28(12):E59. doi: 10.1093/nar/28.12.e59.
[cited by applicant]
Cited By (1)